Hope S. Rugo, MD, professor of Medicine and director of breast oncology and clinical trials education at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses DigniCap, a scalp cooling device to prevent chemotherapy-induced hair loss.
Hope S. Rugo, MD, professor of Medicine and director of breast oncology and clinical trials education at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses DigniCap, a scalp cooling device to prevent chemotherapy-induced hair loss.
Since the approval of DigniCap last December, Rugo says that there has been progress on both the national and worldwide levels, such as the establishment of an international organization that will collaborate on scalp cooling. In the United States, there has been an increase in awareness and uptake of the cooling cap, as well as the creation of another organization providing financial assistance to patients who may not be able to cover the cost of DigniCap.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.